We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Sanofi and Partners Win Approval for Sleeping Sickness Drug and Score Valuable Priority Review Voucher
Sanofi and Partners Win Approval for Sleeping Sickness Drug and Score Valuable Priority Review Voucher
Sanofi and nonprofit partners in Africa have won FDA approval for the first oral treatment for sleeping sickness. In addition to the approval, the FDA granted the partners a priority review voucher (PRV) worth millions of dollars.